- Location
regulatory application
"-
Shell Launches Quest Carbon Capture and Storage Project
Dec 9, 2016As part of its funding arrangements, Shell is publically sharing information on Quest's design and processes to further global adoption of CCS. Quest draws on techniques used by the energy industry for decades and integrates the components ...
-
Canada's Alberta Unveils New Carbon Policy for Oil Sands Sector
Nov 24, 2015Canada's Alberta province Sunday announced a new "climate leadership" plan that includes a cap on greenhouse gas emissions by oil sands producers as it moves to overhaul its image and kick start export opportunities. The cap on emissions ...
Tags: greenhouse gas, oil sands, oil
-
GSK Submitted a New Drug Application to The US FDA for Umeclidinium Bromide Monotherapy
May 3, 2013GlaxoSmithKline (GSK) has submitted a new drug application (NDA) to the US FDA for umeclidinium bromide (UMEC) monotherapy 62.5mcg to treat chronic obstructive pulmonary disease (COPD). The investigational once-daily UMEC, administered ...
Tags: GlaxoSmithKline, FDA Approval, chronic obstructive pulmonary disease
-
GSK and Theravance Have Announced The Submission of a Regulatory Application in Japan
Apr 26, 2013GSK and Theravance have announced the submission of a regulatory application for Anoro Ellipta (UMEC/VI) (62.5/25mcg and 125/25mcg doses) in Japan. UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium ...
-
GlaxoSmithKline and Theravance Have Announced The MAA Submission for Anoro
Jan 11, 2013GlaxoSmithKline and Theravance have announced the MAA submission for Anoro in Europe for patients with chronic obstructive pulmonary disease (COPD). The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 ...
Tags: GlaxoSmithKline, COPD therapy, chronic obstructive pulmonary disease
-
GSK and Theravance Have Submitted a Regulatory Application in The US
Dec 20, 2012GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for the investigational once-daily LAMA/LABA combination medicine, umeclidinium bromide (UMEC/VI), to treat chronic obstructive pulmonary disease (COPD) ...
Tags: GlaxoSmithKline, regulatory application, Medicine, FDA
-
FDA Grants 510(K) Approval to Avery Dennison Medical Solutions' New Non-Cytotoxic
Dec 17, 2012The US Food and Drug Administration (FDA) has granted 510(k) approval to Avery Dennison Medical Solutions' new non-cytotoxic, grade 0 profile transparent wound film dressing, designed to treat catheter-related blood stream infections. ...
Tags: FDA, wound film dressing, clinical product, clinical application
-
GlaxoSmithKline Submitted Regulatory Applications for Eltrombopag in US, Europe
Jun 4, 2012Ligand Pharmaceuticals partner GlaxoSmithKline has submitted regulatory applications in the US and European Union for the use of eltrombopag (Promacta/Revolade) to increase platelet counts in patients with hepatitis C. A supplemental ...
